• NU6300 Targets GSDMD Cys191 to Block Pyroptosis

  2026-09-28

  The reference study identifies NU6300 as a covalent GSDMD inhibitor that reacts with cysteine-191 and interferes with cleavage, palmitoylation, membrane localization, and oligomerization. Its pathway-dependent effects in inflammasome models, together with activity in colitis and sepsis models, provide a mechanistic framework for developing pyroptosis-directed anti-inflammatory compounds.

• 5-Azacytidine Triggers DNA Damage in Myeloma

  2026-09-28

  A preclinical study found that 5-azacytidine induces ATR-associated DNA damage responses and apoptosis in multiple myeloma cells, including therapy-resistant models. Its reported activity and synergy with doxorubicin or bortezomib support further investigation, while the in vitro evidence does not establish clinical benefit.

• LG 101506: RXR Modulator Workflows in TNBC

  2026-09-27

  Use LG 101506 to test whether RXR modulation changes cellular phenotypes in cancer and metabolism models—not to assume a proven effect on PD-L1. This workflow pairs controlled compound handling with orthogonal RXR, checkpoint, and immune-cell readouts, while separating established TNBC findings from new hypotheses.

• Topotecan HCl: Practical Assay Design

  2026-09-26

  A scenario-driven guide to using Topotecan HCl (SKU B2296) in viability, proliferation, and cytotoxicity workflows. It covers mechanism, concentration and solvent planning, interpretation limits, and practical criteria for selecting a supplier without overstating what the available data establish.

• MLN2238: Mapping Proteasome Stress Signaling

  2026-09-25

  Explore how MLN2238, a potent proteasome β5 subunit inhibitor, can reveal the signaling response to proteotoxic stress. This article connects proteasome perturbation with ROS–JNK–CREB biology while distinguishing established findings from practical assay hypotheses.

• Spectrophotometric Assays for Alfuzosin–Tadalafil

  2026-09-25

  Alqahtani and colleagues developed the first reported spectrophotometric methods for quantifying alfuzosin hydrochloride and tadalafil together in a binary mixture. Their absorbance-subtraction and ratio-difference approaches address overlapping spectra and were validated for tablet analysis, offering simpler alternatives to more instrument-intensive assays without establishing clinical or pharmacological effects.

• BKT140 (BL-8040) in CXCR4 Oncology Workflows

  2026-09-24

  Build functional CXCR4 studies around BKT140 (BL-8040): connect receptor expression with chemotaxis, survival, and cell-mobilization readouts. Practical starting conditions and troubleshooting guidance help distinguish target engagement from assay artifacts while keeping imaging evidence in its proper translational context.

• DMXAA and the Endothelial Logic of Tumor Control

  2026-09-24

  DMXAA (Vadimezan) offers a way to interrogate tumor-vessel injury, angiogenic signaling, and cell-death responses. Here, we connect its reported pharmacology to new evidence on endothelial STING-JAK1 biology—while keeping the evidence boundaries clear for translational study design.

• MLN2238: From Proteasome Blockade to Stress Signaling

  2026-09-23

  Explore MLN2238 as a proteasome β5 subunit inhibitor and a tool for studying how proteotoxic stress reshapes cellular signaling. This article connects its target profile with CRTC–CREB findings and practical assay choices, while distinguishing established evidence from cross-model hypotheses.

• MLN2238: From β5 Selectivity to Stress Signals

  2026-09-23

  MLN2238 is a proteasome β5 subunit inhibitor that enables researchers to connect catalytic-site inhibition with ROS, JNK, CREB, and proteostasis outcomes. This article presents a layered assay strategy for distinguishing direct proteasome effects from adaptive stress signaling in oncology and protein-aggregation models.

• Disulfiram Workflows for Proteasome and Cancer Research

  2026-09-22

  Disulfiram enables paired studies of copper-sensitive proteasome inhibition, apoptotic cancer cell death, and inflammasome-linked pyroptosis. This workflow emphasizes matched controls, orthogonal readouts, and practical handling conditions for more interpretable cancer research.

• IBDV VP3 Disrupts IRF7 Antiviral Signaling

  2026-09-22

  The 2025 Frontiers in Cellular and Infection Microbiology study identifies IBDV VP3 as a viral factor that suppresses IRF7-dependent type I interferon signaling and promotes viral replication through proteasome-associated IRF7 degradation. Its paired infection, genetic perturbation, inhibitor, and protein-interaction experiments provide a useful framework for studying how viral proteins redirect host protein-stability pathways.

• SARS-CoV-2 ORF3a Q57H Dampens Apoptosis

  2026-09-21

  The reference study shows that the SARS-CoV-2 ORF3a-Q57H variant reduces pro-apoptotic activity through altered protein localization and weaker activation of the extrinsic apoptotic pathway, rather than through markedly lower total protein expression. Its design separates abundance from function and provides a useful framework for interpreting apoptosis assays and caspase activity measurement in virus–host cell studies.

• ONX-0914 (PR-957) for LMP7 Assays

  2026-09-21

  ONX-0914 (PR-957) provides a selective way to interrogate LMP7-driven cytokine signaling in autoimmune, inflammatory, and airway infection assays. This guide translates immunoproteasome biology into practical workflows, with controls that distinguish LMP7-specific effects from solvent toxicity, broad proteasome inhibition, or altered viral burden.

• AP20187 for Precision Conditional Signaling

  2026-09-20

  AP20187 is a chemical inducer of dimerization that converts engineered fusion proteins into experimentally controllable signaling switches. This guide connects its conditional activation workflow with macrophage–nociceptor research, while separating established product applications from forward-looking assay opportunities.

8584 records 1/573 page Next 12345 下5页 Last page